Sara Ranjbarvaziri, Aliya Zeng, Iris Wu, Amara Greer-Short, Farshad Farshidfar, Ana Budan, Emma Xu, Reva Shenwai, Matthew Kozubov, Cindy Li, Melissa Van Pell, Francis Grafton, Charles E MacKay, Xiaomei Song, James R Priest, Gretchen Argast, Mohammad A Mandegar, Timothy Hoey, Jin Yang
Heart failure with preserved ejection fraction (HFpEF) poses therapeutic challenges due to the limited treatment options. Building upon our previous research that demonstrates the efficacy of histone deacetylase 6 (HDAC6) inhibition in a genetic cardiomyopathy model, we investigate HDAC6's role in HFpEF due to their shared mechanisms of inflammation and metabolism. Here, we show that inhibiting HDAC6 with TYA-018 effectively reverses established heart failure and its associated symptoms in male HFpEF mouse models...
February 26, 2024: Nature Communications